特利加压素治疗肝硬化腹水相关并发症的研究进展

Research progress of terlipressin in the treatment of cirrhotic ascites-related complications

腹水是肝硬化患者失代偿期最为常见的临床症状,并存在于顽固性腹水、低钠血症、肝肾综合征等并发症之中,病情复杂,危害严重。内脏血管扩张是肝硬化腹水相关并发症的关键病理环节,针对该环节治疗有助于消除腹水症状,防止失代偿期肝硬化的进一步恶化。现综述特利加压素在肝硬化腹水相关并发症治疗中的药理基础、临床证据与应用特点,分析尚存在的问题并提出展望。

Ascites is the most common clinical symptom in the decompensated stage of patients with liver cirrhosis,and its co-existence in complex conditions,such as refractory ascites,hyponatremia,hepatorenal syndrome and other complications may harm seriously.Splanchnic vasodilation is the key pathological link of cirrhotic ascites-related complications and the treatment of this link can help to eliminate the symptoms of ascites and prevent the further deterioration of decompensated cirrhosis.This paper summaries the pharmacological basis,clinical evidence and application characteristics of a vasocative drugs-terlipressin in the treatment of cirrhotic ascites-related complications,and further analyzes the problems existing in the current research,then proposes a prospect.